TWD 39.95
(-1.96%)
Breakdown | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 1.04 Billion | 296.03 Million | 66.21 Million | - |
Cost of Revenue | 886.89 Million | 206.47 Million | 23.85 Million | - |
Gross Profit | 157.09 Million | 89.55 Million | 42.36 Million | - |
Operating Expenses | 2.53 Billion | 1.73 Billion | 1.09 Billion | 1.67 Billion |
Selling, General and Administrative Expenses | 467.81 Million | 10.2 Million | 3.1 Million | 369.51 Million |
Research and Development Expenses | 2.06 Billion | 1.38 Billion | 835.72 Million | 1.3 Billion |
Other Expenses | - | 55.4 Million | 70.34 Million | - |
Cost and Expenses | 3.42 Billion | 1.93 Billion | 1.12 Billion | 1.67 Billion |
Operating Income | -2.38 Billion | -1.64 Billion | -1.05 Billion | -1.67 Billion |
Interest Expense | - | - | - | - |
Income Tax Expense | -265.47 Million | -223.32 Million | -196.61 Million | 334.51 Million |
Earnings before Tax | -2.19 Billion | -1.58 Billion | -983.09 Million | -1.67 Billion |
Net Income | -1.92 Billion | -1.35 Billion | -786.47 Million | -1.33 Billion |
Earnings Per Share Basic | -1.20 | -0.78 | -0.45 | -0.87 |
Earnings Per Share Diluted | -1.20 | -0.78 | -0.45 | -0.87 |
Weighted Average Shares Outstanding | 1.6 Billion | 1.74 Billion | 1.74 Billion | 1.53 Billion |
Weighted Average Shares Outstanding (Diluted) | 1.6 Billion | 1.74 Billion | 1.74 Billion | 1.53 Billion |
Gross Margin | 0.15 | 0.30 | 0.64 | - |
EBIT Margin | -1.18 | -4.60 | -11.86 | - |
Profit Margin | -1.85 | -4.58 | -11.88 | - |
EBITDA | -1.22 Billion | -1.36 Billion | -774.86 Million | 669.02 Million |
Earnings Before Tax Margin | -2.28 | -5.55 | -15.92 | - |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
---|---|---|---|---|---|---|
Revenue | 3.6 Billion | 822.16 Million | 455.51 Million | 305.76 Million | 230.89 Million | 51.83 Million |
Cost of Revenue | 2.93 Billion | 702.55 Million | 394.79 Million | 295.37 Million | 157.05 Million | 39.67 Million |
Gross Profit | 674 Million | 119.6 Million | 60.71 Million | 10.38 Million | 73.83 Million | 12.15 Million |
Operating Expenses | 958.32 Million | 870.04 Million | 778.35 Million | 631.15 Million | 565.65 Million | 562.5 Million |
Selling, General and Administrative Expenses | 145.37 Million | 142.35 Million | 147.47 Million | 115.47 Million | 87.08 Million | 117.78 Million |
Research and Development Expenses | 812.95 Million | 727.69 Million | 630.88 Million | 515.67 Million | 478.56 Million | 444.72 Million |
Other Expenses | 25.09 Million | 41.38 Million | - | -5.31 Million | 2.7 Million | 7.36 Million |
Cost and Expenses | 3.88 Billion | 1.57 Billion | 1.17 Billion | 926.52 Million | 722.7 Million | 602.17 Million |
Operating Income | -236.3 Million | -685.88 Million | -717.63 Million | -625.53 Million | -491.81 Million | -540.85 Million |
Interest Expense | 1.04 Million | 525 Thousand | - | 553 Thousand | 2000.00 | - |
Income Tax Expense | -87.44 Million | -107.27 Million | 67.18 Million | -73.01 Million | -56.85 Million | -68.42 Million |
Earnings before Tax | -237.34 Million | -686.4 Million | -545.54 Million | -626.09 Million | -480.18 Million | -540.85 Million |
Net Income | -149.9 Million | -579.13 Million | -478.36 Million | -553.07 Million | -423.33 Million | -472.43 Million |
Earnings Per Share Basic | -0.09 | -0.33 | -0.29 | -0.35 | -0.27 | -0.27 |
Earnings Per Share Diluted | -0.09 | -0.33 | -0.29 | -0.35 | -0.27 | -0.27 |
Weighted Average Shares Outstanding | 1.66 Billion | 1.74 Billion | 1.66 Billion | 1.58 Billion | 1.56 Billion | 1.74 Billion |
Weighted Average Shares Outstanding (Diluted) | 1.66 Billion | 1.74 Billion | 1.66 Billion | 1.58 Billion | 1.56 Billion | 1.74 Billion |
Gross Margin | 0.19 | 0.15 | 0.13 | 0.03 | 0.32 | 0.23 |
EBIT Margin | 0.05 | -0.42 | -0.92 | -1.02 | -0.81 | -4.83 |
Profit Margin | -0.04 | -0.70 | -1.05 | -1.81 | -1.83 | -9.12 |
EBITDA | 184.91 Million | -344.74 Million | -420.57 Million | -311.3 Million | -187.92 Million | -250.56 Million |
Earnings Before Tax Margin | -0.07 | -0.83 | -1.58 | -2.05 | -2.13 | -10.44 |
DANHOS13
ODHN
VISN
ACR
NEWTI
BLG